Fly News Breaks for October 21, 2015
SNTA
Oct 21, 2015 | 12:29 EDT
FBR Capital analyst Christopher James downgraded Synta Pharmaceuticals to Market Perform from Outperform with a $2 price target after the company decided to terminate the Phase 3 trials of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma.
News For SNTA From the Last 2 Days
There are no results for your query SNTA